2Goto Y. Glucosidase Inhibitor. Diabetes Frontier, 1992, 3(6): 557-564.
31，Saltiel AR,Olefsky JM.Thiazolidinediones in the treatment of insulin resistance and type Ⅱ diabetes.Diabetes,1996,45(12):1661～1669.
42，Mori Y,Murakawa Y,Okada K,et al. Effect of troglitazone on body fat distribution intype 2 diabetic patients. Diabetes Care,1999,22(6):908～912.
53，Kawai T,Takei I,Oguma Y,et al. Effects of troglitazone on fat distribution in thetreatment of male type 2 diabetes. Metabolism,1999,48(9):1102～1107.
64，Young PW,Buckle DR,Cantello BC,et al. Identification of high-affinity binding sitesfor the insulin sensitizer rosiglitazone(BRL-49653)in rodent and human adipocytes using aradioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J PharmacolExp Ther,1998,284(2):751～759.
75，Song J,Walsh MF,Igwe R,et al. Trolitazone reduces contraction by inhibition ofvascular smooth muscle cell Ca2+ currents and not endothelial nitric oxideproduction. Diabetes,1997,46(4):659～664.
86，Walker AB,Chattington PD,Buckingham RE,et al. The thiazolidinedionerosiglitazone(BRL-49653)lowers blood pressure and protectsagainst impairment of endothelial function in Zucker fatty rats. Diabetes,1999,48(7):1448～1453.
97，Sung BH,Lzzo JL，Jr Dandona P，et al. Vasodilatory effects of troglitazone improveblood pressure at rest and during mental stress in type 2 diabetes mellitus.Hypertension,1999,34(1):83～88.
108，Freed MI,Allen A,Jorkasky DK,et al. Systemic exposure to rosiglitazone is unaltered byfood. Eur J Clin Pharmacol,1999,55(1):53～56.
